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Introduction 
Significant postoperative bleeding is a common risk of cardiac surgery with approximately 
3.5% of patients requiring surgical re-exploration.1 Re-exploration is associated with adverse 
outcomes including infections, ischemia, and increased 30-day mortality.2 Similar adverse 
outcomes are related to erythrocyte transfusions associated with cardiac surgery,3 in 
addition to the immunologic and administrative hazards of transfusion.4 These risks are 
important because the majority of patients undergoing cardiac surgery receive a blood 
transfusion despite the lack of evidence to support liberal transfusion strategies.5 The 
frequency and significance of bleeding following cardiac surgery warrants investigation of the 
hematologic changes throughout the procedure. This review focuses on the 
(patho)physiology of platelet-derived microvesicles in the setting of cardiovascular surgery, a 




Microvesicles, formerly called microparticles,6,7 are released from the cell membrane of a 
range of cells, including monocytes, erythrocytes and endothelial cells, during activation or 
apoptosis.8,9 They are 10-200 nm in diameter and retain surface antigens specific to their 
parent cell. Platelet microvesicles (PMV) are the most abundant in normal plasma.7,10 PMV 
have an important role in the initiation and propagation of coagulation, providing a key focus 
for hematologic research to improve the safety of cardiac surgery. Their discovery occurred 
when the clotting time of blood was prolonged following high-speed centrifugation during 
which PMV became separated from platelet-dense serum, suggesting that PMV enhance 
coagulation.11 Further research using centrifugation and electron microscopy revealed that 
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Production of PMV 
Following endothelial injury, inflammatory mediators including glycoprotein Ib/IX and 
endothelial von Willebrand factor (vWf) trigger a rise in cytosolic calcium which stimulates 
calpain to trigger platelet activation and the release of adenosine diphosphate (ADP), 
thrombin, tissue factor (TF) and thromboxane A2.
9 (Figure 1).  
In the non-activated state the phospholipid bi-layer of the platelet membrane is held in 
asymmetry as a result of the enzyme transporters flippase and aminophospholipid 
translocase.13 A rise in cytosolic calcium following platelet activation has a key role in the 
production of PMV through its action on these enzymes (Figure 2). Flippase and 
aminophospholipid translocase are inhibited, disabling them from holding phosphatidylserine 
(PS) and phosphatidylethanolamine on the inner membrane layer,14 while activation of 
floppases and lipid scramblase causes rapid outward translocation of PS and loss of 
membrane asymmetry.15,16 The movement of PS to the outer surface of the platelet 
membrane activates factor X and prothrombin, thus propagating the coagulation cascade 
and the formation of PMV.17,18 
 
In addition to the loss of membrane asymmetry, activation of gelsolin and calpain causes is 
alteration of the platelet actin cytoskeleton and a change in platelet shape, which in itself 
produces PMV.19,20 However, PMV are still produced when calpain is inhibited.21 There are 
consequentially multiple pathways to PMV production, and disabling one pathway may still 
allow PMV to be shed. 
 
Procoagulant activity 
The inability to produce lipid scramblase in Scott syndrome results in platelets that are 
unable to lose membrane asymmetry to allow surface expression of PS and form 
microvesicles.9 Platelets have rapid PS expression, allowing prompt promotion of 
coagulation at the sites of endothelial injury;18 the removal of PS from the PMV surface 
decreases the rate of thrombin production,22 providing evidence that the production of PMV 
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is critical to physiological coagulation. The phenotype of a microvesicle alters its function; 
increasing expression of PS and TF enhances thrombin generation.22 Some PMV express 
anti-coagulant receptors, suggesting there may be a role for PMV in regulating hemostasis.23 
Procoagulant receptors are more densely expressed on the surface of PMV than the parent 
platelet by up to 100-fold.24 Increased concentrations of circulating PMV promote platelet 
aggregation, leading to thrombus formation.25 PS expression on the outer surface of the 
microvesicle encourages coagulation due to its ability to bind and stimulate several 
coagulation factors through the interaction with their gamma-carboxyglutamic acid domains. 
These factors include factors IIa, Va, VIII, IXa (Figure 3).26 TF expressed on the surface of 
PMV initiates coagulation by activating factor VII to recruit platelets and initiate the pathway 
to thrombus formation in the response to vascular injury.27 However increased TF 
expression does not always correlate with increased coagulation, suggesting that other 
factors are similarly important.22,28Integrin α11bβ3, another receptor expressed on the outer 
PMV surface, has a role in binding PMV to fibrinogen to cause platelet adhesion.29 
 
Microvesicles taken from the pericardial cavity of patients undergoing cardiopulmonary 
bypass promote thrombin generation.30 Berckmans et al demonstrated that the introduction 
of microvesicles in vitro to plasma results in thrombin generation.26 Interestingly, they 
proposed that small amounts of thrombin generate activated protein C (APC), which can 
have anticoagulant properties by inactivating factors Va and VIIIa.26 PMV also support APC 
generation, which leads to a hypothesis that PMV have a role in homeostasis in thrombosis 
by possessing both anti- and pro-coagulant triggering mechanisms.23,31 
 
Clearance 
The first report investigating the half-life of transfused PMV in vivo demonstrated a plasma 
half-life of under six hours in 11 patients with thrombocytopenia awaiting platelet 
transfusion.32 This is faster than the rate of circulating platelet clearance. Microvesicles 
released following dobutamine stress echocardiography are cleared from the circulation 
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within an hour.33 These studies suggest that microvesicles exert their actions in a very short 
time-frame and that there exists separate pathways for microvesicle and platelet clearance. 
There are significantly higher numbers of circulating microvesicles in splenectomised mice 
versus non-splenectomised mice, suggesting that the spleen is the site of microvesicle 
clearance.34 Following opsonisation of microvesicles, macrophages can then phagocytose 
particles up to 2µm in size.35 The process is very rapid, with maximum uptake occurring at 
one hour. 
Platelet microvesicles decline more gradually in thawed fresh frozen plasma, by 50% over 
five days. The resulting decline in procoagulant activity was 29%, indicating that PMV 
numbers decrease in vitro and contribute to in vivo coagulation.10 The same study also 
demonstrated that removal of PMV by filtration results in reduced thrombin generation, and 
that restoration of PMV into the infusion increased the ability for coagulation. The cause of 
PMV decline in vitro is only speculated; Matijevic et al suggests that extacellular 
phospholipases may degrade the microvesicles to sub-detectable volumes or that 
microvesicle coupling to other microvesicles or platelets occurs, forming larger aggregates.36 
The decline in microvesicle numbers may have been a result of proteases degrading 




Laboratory tests and PMV 
The standard method for monitoring coagulation during CPB is the Activated Clotting Time 
(ACT) of whole blood. However, this has poor reproducibility, with variation between 
activators and between devices, and has no correlation with heparin concentration.37,38 ACT 
has no role in evaluation of platelet or PMV function. The activated partial thromboplastin 
time and the prothrombin time are used in laboratory practice to assess the intrinsic and 
extrinsic coagulation pathways respectively, but since they are performed on cell-free 
plasma neither of these tests is sensitive or specific enough for the complete assessment of 
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either perioperative coagulation status or PMV activity. Tests of the visco-elastic properties 
of whole blood, such as thromboelastography, allow more precise evaluation of perioperative 
coagulopathy, however thromboelastography does not seem to be effective at analysing 
PMV populations.39 The standard method for evaluating PMV is flow cytometry (see below), 





Antiplatelet drug use before cardiac surgery increases bleeding complications.40,41 Aspirin 
inhibits cyclooxygenase-1 derived thromboxane A2 in platelets, limiting cytosolic calcium 
increases to reduce aggregation. Aspirin ingestion for seven days does not affect either the 
number or surface expressions of PMV.42 Clopidogrel acts through the inhibition of ADP-
induced aggregation. ADP produced from activated platelets triggers G-protein coupled 
receptors to increase cytosolic calcium to cause PMV production.43 Clopidogrel use in the 24 
hours prior to cardiac surgery has an odds ratio of 2.4 for excessive bleeding compared to 
patients not receiving clopidogrel.40 The plasma concentration of clopidogrel is inversely 
proportional to the number of PMV in patients with stable coronary artery disease, 
suggesting clopidogrel reduces the production of PMV.44 Similarly, plasma endothelial 
microvesicle numbers are reduced after administration of clopidogrel.45 However, one study 
found that anti-platelet drugs did not have an effect on populations of circulating PMV.46 
These conflicting results warrant further investigation into the effect of antiplatelet agents on 
PMV populations. 
Anticoagulants 
Heparin inhibits thrombin via anti-thrombin III, but does not affect surface-bound thrombin.47 
Muriithi et al found that a delayed heparin-induced impairment of platelet aggregation occurs 
in patients prior to CPB, which may suggest that platelet defects previously thought to be 
solely the result of passage through the bypass circuit may result from interaction with 
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heparin.48 Although Muriithi's study did not investigate PMV, their formation occurs 
simultaneously with platelet activation and therefore heparinisation may result in decreased 
PMV numbers. 
 
Anesthetics and other drugs 
Currently no studies have investigated the effect of propofol or volatile anesthetics on PMV 
populations, however propofol does inhibit both intra-operative and post-operative platelet 
aggregation.49,50 Given the hemodynamic effects of anesthetic drugs, changes in shear 
stress within the circulation may be expected to modify platelet and PMV behaviour, but 




A variety of crystalloid and colloid fluids, and blood components, are administered during 
surgery and CPB. Hemodilution reduces blood viscosity, allowing potentially faster blood 
flow and increased shear stresses within the cardiovascular system. However, there are no 
published data on how this might affect PMV. 
 
 
Microvesicles in health and disease 
Females have more circulating PMV than males, although this difference is reduced 
following the menopause.7 Low or normal levels of PMV occur in pre-eclampsia, while 
systemic lupus erythematosus, paroxysmal nocturnal hemoglobinuria, myeloproliferative 
diseases, venous thromboembolism, diabetes mellitus, acute coronary syndrome, and 
chronic renal failure result in raised PMV numbers.51 
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PMV in cardiac surgery 
Cardiopulmonary bypass 
The process of CPB induces hematologic changes via various pathways, including the 
passage of blood through the circuit causing activation of coagulation factors, adhesion of 
blood components to the circuit, and hemodilution as the priming solution mixes with the 
patient's blood. The effect of CPB on coagulation is significant; excessive bleeding is more 
common in patients undergoing on-pump cardiac surgery than in those undergoing off-pump 
cardiac surgery.52 However,circulating fresh blood through a miniaturized CPB circuit does 
not stimulate PMV production,53 suggesting that surgical trauma is more of a stimulus to 
PMV production than CPB. 
 
Shear stress 
Cardiopulmonary bypass is usually performed with roller pumps, rather than centrifugal 
pumps, despite the generation of shear forces that can cause hemolysis, and spallation of 
the pump head tubing.54,55 There is no evidence favoring either type of pump in terms of 
hematologic or coagulation parameters, postoperative blood loss, blood transfusion, 
neurologic outcome, or mortality,41,56-58 since the effects of antifibrinolytic drugs and mild 
hypothermia probably overshadow any small differences between pump types.41 However, 
damage to platelets and red cells, and the inflammatory response, may be worse with 
prolonged CPB using roller pumps.56,59,60 Shear stress causes the platelets to bind vWf,61 the 
surrounding hydrodynamic forces inducing change in platelet shape,62 and hence the 
production of PMV, but there are no published data on the effect of pump type on PMV. 
 
Adhesion 
Despite complement activation during CPB, PMV numbers decrease even after hemodilution 
is accounted for.63 These findings suggest that adhesion to the circuit,64,65 or recruitment to 
thrombus formation within the surgical field, decreases the PMV population faster than they 
are being produced. The thrombogenic surface of the CPB circuit encourages platelet 
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activation and the production of PMV,66 though this effect is reduced with bio-compatible 
coatings in the CPB circuit.67 Fibrin and fibrinogen adhere to the surface, causing thrombin 
to be deposited, which then binds platelet receptors causing their deposition on the circuit 
surface.62 PMV bind to collagen type I, fibrinogen, vWf, and also to immobilized platelets 
already bound to thrombogenic surfaces. Due to the sub-micron size of PMV, they may be 
able to withstand extreme shear stress, remaining in position to encourage further thrombus 
formation on extra-corporeal surfaces.68 
 
Hemodilution 
The prime fluid mixes with circulating blood, diluting coagulation factors both during bypass 
and in the immediate post-bypass period.69 As mean arterial pressure is low during CPB 
there is an increased risk of thrombotic events during this time, counteracted by the 
reduction in pro-coagulant substances, cells and PMV by hemodilution. The risk of adverse 
hematologic events occurs post-operatively when these key players in the coagulation 
cascade have not recovered to pre-bypass levels, leading to a coagulopathy. 
 
Cell salvage 
Mechanical cell salvage removes the majority of platelets and virtually all PMV,70 since PMV 
and coagulation factors are removed in the washing process. Despite this reduction, the 
adverse event incidence following autotransfusion is 0.027% in contrast to 0.14% with 
allogeneic blood transfusions.71 However, postoperative platelet counts two hours after CPB 
are the same between control and cell-salvaged patients, although postoperative blood loss 
was less in patients who had received cell-salvaged blood.72 Further work is required to 
elucidate the pattern of PMV activity during cardiac surgery and the potential impact on 
perioperative coagulation. 
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Surgical trauma 
Surgical trauma causes endothelial and soft tissue injury which leads to PMV formation.51,73-
75 The result is platelet recruitment, and subsequent thrombus formation. Surgical trauma 
increases microvesicle production in cardiac surgery in addition to the effect of CPB, since 
pericardial blood contains higher concentrations of coagulation markers and microvesicles 
than blood in the left ventricle.64,65,76 
 
Left ventricular assist devices 
There are no published data on PMV formation in implanted LV assist devices, although 
bleeding and thrombosis are a significant risk in this population.77 
 
Hypothermia 
Hypothermia below 31.3˚C during cardiac surgery is associated with decreased platelet 
function and decreased formation of PMV in heparinised blood, leading to increased 
bleeding.78 
 
Patients undergoing CABG or trauma surgery with low pre-operative PMV counts are at an 
increased risk of blood transfusion.39,79 Targeting PMV production and clearance to increase 
circulating numbers may reduce clinically important adverse effects such as bleeding, 
although larger studies with sampling of blood at multiple time points are required to better 
delineate the precise perioperative role of PMV. The infusion of PMV may be a potential 
future treatment for surgery-related bleeding with minimal transmission of pathogens or 
threat of immune response.80 
 
 
Isolating and studying microvesicles 
Many different methods are currently used to isolate microvesicles from whole blood. The 
International Society for Extracellular Vesicles is developing protocols for the extraction of 
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microvesicles to standardise research internationally.6 The key process used in the majority 
of studies is the collection of whole blood, which is then centrifuged twice to obtain platelet-
poor plasma (PPP). PPP can be stored at -80˚C and thawed prior to analysis by flow 
cytometry. Although many studies follow an interpretation of these methods, the differences 
in collection methods and centrifugation protocols have led to variation in reported 
microvesicle concentrations between studies.51  
Blood for microvesicle studies should be taken with minimal shear stress; this can be 
achieved by a slow draw-back into a syringe from a central or arterial line or via 
venepuncture using a needle larger than 21 gauge.8 This blood should preferably be 
collected into plastic tubes with sodium citrate anticoagulant prior to centrifugation, however 
other anticoagulants such as lithium heparin can be used. 8,81 
Centrifugation at low speeds may fail to obtain PPP, and overly high speeds can cause 
microvesicle loss or cause microvesicle doublets to form. Burnouf et al concluded that an 
initial centrifugation at 2,500g for 15 minutes within two hours of collection, followed by 
aspiration of PPP and subsequent centrifugation of the supernatant at the same speed and 




Pathologies such as Scott syndrome demonstrate, along with clinical and laboratory studies, 
that PMV have a crucial role in hemostasis. Although PMV could be used, among other 
predictors of transfusion risk such as pre-operative APTT and hemoglobin, to identify 
patients at risk of bleeding complications, current methods of identifying PMV populations 
are inadequate for the rapid and widespread use of PMV for prognostic purposes. However, 
the increased availability of flow cytometry equipment and refined protocols for isolating and 
investigating microvesicle numbers has enabled advances in our knowledge of sub-micron 
hematologic changes throughout cardiac surgery, though there is still much that is not known 
in this field. Future advances may see the widespread use of pre-operative PMV counts to 
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predict peri-operative bleeding complications, and as an assessment of platelet function 




Figure 1: The hematologic response to endothelial injury leading to the formation of a 
stable hemostatic plug. 
 
Figure 2: In the non-activated state (left), the platelet membrane is held in asymmetry 
by movement of phosphatidylserine and phosphatidylethanolamine onto the inner 
surface. The increase in cytosolic Ca2+ associated with platelet activation results in 
the loss of asymmetry and the production of PMV. 
 
Figure 3: PMV have an important role within the coagulation cascade. Circled factors bind with 
PS positive PMV to stimulate coagulation factor activation. Integrin and tissue factor are 
expressed on receptor-specific PMV membranes and these surface proteins interact with the 
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